The History of Therapeutic Aerosols: A Chronological Review

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 30, Issue 1, 2017, Pages 20-41

  Stein, Stephen W ^a   Thiel, Charles G ^b  

^a 3M Drug Delivery Systems 3M Center Building 260 3A 05   (United States)

^b NONE   (United States)

Author keywords

atropine; dry powder inhaler; inhaler; metered dose inhaler; nebulizer; therapeutic aerosol

Indexed keywords

ATROPINE; BCG VACCINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CROMOGLYCATE DISODIUM; EPINEPHRINE; ERGOTAMINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; HYDROCORTISONE; IPRATROPIUM BROMIDE; ISOPRENALINE; LEVALBUTEROL; LIOTHYRONINE; MEASLES VACCINE; METHYLPHENIDATE; MOMETASONE FUROATE; NEOMYCIN; ORCIPRENALINE; PHENYLEPHRINE; PHENYLEPHRINE TARTRATE; PIRBUTEROL ACETATE; PROCATEROL; SALBUTAMOL; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ASTHMA; ATTENTION DEFICIT DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOLOGY; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRY POWDER INHALER; EQUIPMENT DESIGN; HANGOVER; HISTORY OF MEDICINE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICAL RESEARCH; METERED DOSE INHALER; MIGRAINE; NEBULIZER; PRODUCT DEVELOPMENT; REVIEW; TACHYCARDIA; TUBERCULOSIS; AEROSOL; HISTORY; LUNG; METABOLISM; QUALITY OF LIFE;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; DRY POWDER INHALERS; EQUIPMENT DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; LUNG; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; QUALITY OF LIFE;

EID: 85010332994     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2016.1297     Document Type: Review

References (128)

1. Breasted JH: The Edwin Smith Surgical Papyrus. University of Chicago Press, Chicago, IL; 1930.
2. Ebbell B: The Papyrus Ebers: The Greatest Egyptian Medical Document (translation to English). Levin and Munksgaard, Copenhagen; p. 67, 1937.
3. Sanders M: Inhalation therapy: An historical review. Prim Care Respir J. 2007;16:71-81.
4. Alizadeh A, Moshiri M, Alizadeh J, and Balali-Mood M: Black henbane and its toxicity - A descriptive review. Avicenna J Phytomed. 2014;4:297-311.
5. Kritikos PG, and Papadaki SP: The early history of the poppy and opium. Bull Narcotics. 1967;19:17-38.
6. Heydari M, Hashempur MH, and Zargaran A: Medicinal aspects of opium as described in Avicenna's Canon of Medicine. Acta Med Hist Adriat. 2013;11:101-112.
7. Gandevia B: Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J. 1975;51 (Suppl. 7):13-20.
8. Viswanathan R: Historical aspects of bronchial asthma. Indian J Chest Dis. 1964;6:165-169.
9. Anderson PJ:History of aerosol therapy: Liquid nebulization to MDIs to DPIs. Respir Care. 2005;50:1139-1150.
10. Shehata M: History of inhalation therapy. Internet J Health. 2008;9:1-9.
11. Solis-Cohen J: Inhalation in the Treatment of Disease, Its Therapeutics and Practice: A Treatise On the Inhalation of Gases, Vapors, Nebulized Fluids, and Powders. Lindsay & Blakiston, Philadelphia; pp. 19-21,193-340, 1867.
12. Tissier PLA: Pneumotherapy, including aerotherapy and inhalation methods and therapy, volume 10. In: SS Cohen (ed). A System of Physiologic Therapeutics. P. Blakiston's Son & Co., Philadelphia, PA. pp. 440-451, 1903.
13. Brenner BE: Where have we been? The history of acute asthma, In: BE Brenner (ed). Emergency Asthma. Marcel Dekker, Inc., New York; pp. 1-32, 1999.
14. Bostock J, and Riley HT: The Natural History of Pliny, Volume V (translation to English). Henry G. Bohn, London; 1856.
15. Lee MR: The history of Ephedra (ma-huang). J R Coll Phys Edinburgh. 2011;41:78-84.
16. Scudder JM: Eclectic Manual No. 2 on the Use of Medicated Inhalations in the Treatment of Diseases of the Respiratory Organs. John M Scudder's Sons, Cincinnati, OH; p. 21, 1895.
17. Mudge J: A Radical and Expeditious Cure for a Recent Catarrhous Cough, 2nd Edition. E. Allen, London; pp. 131-147, 1778.
18. Sanders M: 2016, Lynch inhaler. www.inhalatorium.com/ wpcproduct/lynch-inhaler/ (accessed September 8, 2016).
19. Nikander K, and Sanders M: The early evolution of nebulizers. Medicamundi. 2010;54:47-53.
20. Long CW: An account of the first use of sulphuric ether by inhalation as an anaesthetic in surgical operations. South Med Surg J. 1849;5:705-713.
21. Steward DJ: The early history of anaesthesia in Canada: The introduction of ether to upper Canada. 1847, Can Anaesthet Soc J. 1977;24:153-161.
22. Sneader W: Systemic medicine. In: W Sneader (ed). Drug Discovery - A History. John Wiley and Sons Ltd., Chichester, West Sussex, England; pp. 74-87, 2005.
23. Warren I: The Household Physician; for the Use of Families, Planters, Seamen, and Travellers. Being a Brief Description, in Plain Language, of all the Diseases of Men, Women, and Children, with the Newest and Most Approved Methods of Curing Them. Higgins, Bradley, and Dayton; Boston, MA. pp. 189-224, 1859.
24. Bleyer JM: A new method of laryngeal and bronchial medication by means of a spray and tube during the act of deep inspiration: Read in the Section of Laryngology and Otology at the Forty-first Annual Meeting of the American Medical Association, Nashville, Tenn., May, 1890. J Am Med Assoc. 1890;XV:634-636.
25. Wyeth J: An Epitome of Therapeutics with Special Reference to the Laboratory Products of John Wyeth and Brother. John Wyeth & Brother, Inc., Philadelphia, PA; pp. 251-252; 1901.
26. Helbing H, and Pertsch G: Collodion mixture. U.S. patent 628,463; July 11, 1899.
27. Clark AR: Medical aerosol inhalers: Past, present, and future. Aerosol Sci Technol. 1995;22:374-391.
28. Rau JL: The inhalation of drugs: Advantages and problems. Respir Care. 2005;50:367-382.
29. Anderson PJ: Delivery options and devices for aerosolized therapeutics. Chest. 2001;120:89S-93S.
30. Brennan P, Crispo A, Zaridze D, Szeszenia-Dabrowksa N, Rudnai P, Lissowska J, Fabiánová E, Mates D, Bencko V, Foretova L, Janout V, Fletcher T, and Boffetta P: High cumulative risk of lung cancer death among smokers and nonsmokers in central and eastern Europe. Am J Epidemiol. 2006;164:1233-1241.
31. ElliottHL, andReid JL: The clinical pharmacology of a herbal asthma cigarette. Br J Clin Pharmacol. 1980;10:487-490.
32. IMS Health (MIDAS January 2016).
33. Chen BT, Namenyi J, Yeh HC, Mauderly JL, and Cuddihy RG: Physical characterization of cigarette smoke aerosol generated from a Walton smoke machine. Aerosol Sci Technol. 1990;12:364-375.
34. Beatson G: Practical papers on the materials of the antiseptic method of treatment, Vol. III, on spray producers. In: J Coat (ed). Glasgow Medical Journal, edited for the West of Scotland Medical Association, Vol. XIV. Alex and Macdougall, Glasgow; pp. 461-484, 1880.
35. Abramson HA: Principles and practice of aerosol therapy of the lungs and bronchi. Ann Allergy. 1946;4:440-456.
36. Scudder JM: On the Use of Medicated Inhalations, in the Treatment of Diseases of the Respiratory Organs. Moore, Wilstach & Baldwin, Printers, Cincinnati, OH; pp. 27-37, 1867.
37. Warren I: Inhaler. U.S. patent 8,813; March 16, 1852.
38. Jackson WA: The carbolic smoke ball. Pharm Historian. 1984;14:9-10.
39. Clarfield AM: The strange case of Miss E.C. Carlill versus the Carbolic Smoke Ball Company. Ann Long Term Care. 2005;13:46-47.
40. Newton A: Inhaling apparatus. U.K. patent 1161; May 7, 1864.
41. Fields MR: Inhalator, U.S. patent 2,470,296; May 17, 1949.
42. Krasno LR, and Rhoads PS: The inhalation of penicillin dust; its proper role in the management of respiratory infections. Am Practitioner. 1949;3:649-653.
43. Solis-Cohen S: The use of adrenal substance in the treatment of acute asthma. JAMA. 1900;34:1164-1166.
44. O'Callaghan C, Nerbrink O, and Vidgren MT: The history of inhaled drug therapy, In: H Bisgaard, C O'Callaghan, and GC Smaldone (eds). Drug Delivery to the Lung. Informa Healthcare, New York; pp. 1-20, 2007.
45. Gelfand ML: Administration of cortisone by the aerosol method in the treatment of bronchial asthma. N Engl J Med. 1951;245:293-294.
46. Thiel CG: From Susie's question to CFC-free: An inventor's perspective on forty years of MDI development and regulation. Respir Drug Deliv. 1996;1:115-123.
47. Freedman T: Medihaler therapy for bronchial asthma. Postgrad Med. 1956;20:667-673.
48. Franklin W, Lowell FC, Michelson AL, and Schiller IW: Aerosolized steroids in bronchial asthma. J Allergy. 1958; 29:214-221.
49. Newman S: Additional technology for metered dose inhalers. In: S Newman (ed). Respiratory Drug Delivery: Essential Theory & Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 217-256, 2009.
50. Bloomfield P, Crompton GK, and Winsey NJP: A tube spacer to improve inhalation of drugs from pressurized aerosols. Br Med J. 1979;2:1479.
51. Nikander K, Nicholls C, Denyer J, and Pritchard J: The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv. 2014;27(S1):S4-S23.
52. Dolovich M, Ruffin R, Corr D, and Newhouse MT: Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest. 1983;84:36-41.
53. Newman SP, Moren F, Pavia D, Little F, and Clarke SW: Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124:317-320.
54. Lands AM, Arnold A, McAuliff JP, Luduena FP, and Brown TG: Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967;214:597-598.
55. Bryan J: Ventolin remains a breath of fresh air for asthma sufferers, after 40 years. Pharm J. 2007;279:404-405.
56. Bell JH, Hartley PS, and Cox JSG: Dry powder aerosol I: A new powder inhalation device. J Pharm Sci. 1971;60: 1559-1564.
57. Nerbrink O, Dahlbäck M, and Hansson HC: Why do medical nebulizers differ in their output and particle size characteristics? J Aerosol Med. 1994;7:259-276.
58. Cipolla DC, Clark AR, Chan I, Gonda I, and Shire SJ: Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. S.T.P. Pharma Sci. 1994;4:50-62.
59. O'Callaghan C, and Barry PW: The science of nebulized drug delivery. Thorax. 1997;52(S2):S31-S44.
60. Lang RJ: Ultrasonic atomization of liquids. J Acoust Soc Am. 1962;34:6-9.
61. Leach C: The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50:1201-1206.
62. The Montreal Protocol on substances that deplete the ozone layer, Final Act (Nairobi: UNEP 1987). Federal Register. 1994; 59 FR 56276-56298.
63. Molina M, and Rowland F: Stratospheric sink for chlorofluoromethanes: Chlorine atom-catalysed destruction of ozone. Nature. 1974;249:810-812.
64. Atkins PJ: Transition to HFA MDIs: How did we get here and where are we going? Respir Drug Deliv. 2006;1: 83-90.
65. Rogueda P, Lallement A, Traini D, Iliev I, and Young PM: Twenty years of HFA pMDI patents: Facts and perspectives. J Pharm Pharmacol. 2012;64:1209-1216.
66. Purewal TS, and Greenleaf DJ: Medicinal aerosol formulations. GB8828477; 1989.
67. Heiskel E, and Schmieder W: Druckgaspackung und treibmittel für aerosole. DE3905726A1; 1990.
68. Weil HH, and Daab O: Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen. DE4003272A1; 1990.
69. Stein SW, Sheth P, and Myrdal PB: Advances in metered dose inhaler technology: Hardware development. AAPS PharmSciTech. 2014;15:326-328.
70. Ross DL, and Gabrio BJ: Advances in metered dose inhaler technology with the development of a chlorofluorocarbonfree drug delivery system. J AerosolMed. 1999;12:151-160.
71. Vervaet C, and Byron PR: Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 1999;186: 13-30.
72. Wu Z, Thatcher ML, Lundberg JK, Ogawa MK, Jacoby CB, Battiste JL, and Ledoux KA: Forced degradation studies of corticosteroids with an alumina-steroid-ethanol model for predicting chemical stability and degradation products of pressurized metered-dose inhaler formulations. J Pharm Sci. 2012;101:2109-2122.
73. Shrewsbury SB, Armer TA, Newman SP, and Pitcairn G: Breath synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharm. 2008; 356:137-143.
74. Gabrio BJ, and Velasquez DJ: Inventors; 3M Innovative Properties Company, assignee. Slow spray metered dose inhaler. U.S. patent 6,615,826; September 9, 2003.
75. Leach CL, Davidson PJ, Hasselquist BE, and Boudreau RH: Lung deposition of HFA-134a beclomethasone is greater than that of chlorofluorcarbon fluticasone and chlorofluorcarbon beclomethasone: A cross-over study in health volunteers. Chest. 2002;122:510-516.
76. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, and Colice GL: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215-1222.
77. Postma DS, and van den Berge M: Small airway dysfunction in asthma and COPD: Consequences for therapy and the future. Respir Drug Deliv Europe. 2013;1:1-12.
78. van den Berge M, ten Hacken NHT, van der Wiel E, and Postma DS: Treatment of the bronchial tree from beginning to end: Targeting small airway inflammation in asthma. Allergy. 2013;68:16-26.
79. U.S. Food and Drug Administration: Guidance for industry: Integration of dose-counting mechanisms into MDI drug products. 2003. (http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ ucm071731.pdf) (accessed September 8, 2016).
80. Woodcock A: Responsible inhaler development in article 5 countries: Navigating the scientific, regulatory, political and commercial challenges. Respir Drug Deliv. 2010;1:121-129.
81. U.S. Food and Drug Administration: Consumer update: Primatine Mist with chlorofluorocarbons no longer available after December 31, 2011. (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm247196.htm) (accessed September 8, 2016).
82. Chrystyn H: The Diskus: A review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61: 1022-1036.
83. Atkins PJ: Dry powder inhalers: An overview. Respir Care. 2005;50:1304-1312.
84. Frijlink HW, and De Boer AH: Dry powder inhalers for pulmonary drug delivery. ExpertOpinDrugDeliv. 2004;1:67-86.
85. Hill M: Characteristics of an active multiple dose dry powder inhaler. Respir Drug Deliv. 1994;IV:109-116.
86. Newman S, and Peart J: Dry powder inhalers. In: S Newman (ed). Respiratory Drug Delivery: Essential Theory & Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 257-307, 2009.
87. Staniforth JN: Pre-formulation aspects of dry powder aerosols. Respir Drug Deliv. 1996;V:65-73.
88. Zeng XM, Tee S-K, Martin GP, and Marriott C: Improving the delivery efficiency of dry powder inhalers (DPIs) by adding fine carrier particles to powder formulations. Thorax. 1996;51(S3):A74.
89. Zeng XM, Martin GP, Tee S-K, and Marriott C: The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm. 1998;176:99-110.
90. Islam N, Stewart PJ, Larson I, and Hartley P: Lactose surface modification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose interactive mixtures? Pharm Res. 2004;21: 492-499.
91. Jones MD, and Price R: The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res. 2006;23:1665-1674.
92. Staniforth JN: Nasal and pulmonary powder opportunities: New drugs and formulations for rapid systemic onset. Respir Drug Deliv. 2006;1:249-256.
93. Mueller-Walz R, Fueg LM, Niederlaender C, Pieles U, and Wirth A: Ternary additives: Manipulation and control with magnesium stearate. Respir Drug Deliv. 2006;1:343-350.
94. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebrai A, Eskew ML, Mintzes J, Deaver D, Lotan N, and Langer R: Large porous particles for pulmonary drug delivery. Science. 1997;276:1868-1872.
95. Swenson C, Laseman J, and Busse W: Combination of salmeterol (SAL) and fluticasone (FP) works synergistically to inhibit airway inflammation post allergen challenge. J Allergy Clin Immunol. 2003;111:S126.
96. Nelson HS, Chapman KR, Pyke SD, Johnson M, and Pritchard JN: Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112: 29-36.
97. Newman S: Nebulizers. In: SNewman (ed). RespiratoryDrug Delivery: Essential Theory & Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 135-176, 2009.
98. Knoch M, and Wunderlich E: In-vitro assessment of a new efficient nebulizer system for continuous operation. Respir Drug Deliv. 1994;IV:265-271.
99. Newman S: Emerging inhaler technologies. In: S Newman (ed). Respiratory Drug Delivery: Essential Theory & Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 309-336, 2009.
100. Dalby RN, Spallek M, and Voshaar T: A review of the development of the Respimat soft mist inhaler. Int J Pharm. 2004;283:1-9.
101. Gansslen M: Uber inhalation von insulin. Klin Wochenschr. 1925;4:71.
102. Niven RW: Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151-231.
103. Wolff RK: Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11:197-219.
104. Patton JS, and Platz RM: Aerosol insulin - A brief review. Respir Drug Deliv. 1994;IV:65-74.
105. Heinemann L: The failure of Exubera: Are we beating a dead horse? J Diabetes Sci Technol. 2008;2:518-529.
106. Cavaiola TS, and Edelman S: Inhaled insulin: A breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36: 1275-1289.
107. LaMattina J: Challenges in commercializing inhaled insulin. Available at: www.forbes.com (Last accessed August 23, 2013).
108. Berenson A: Weak sales prompt Pfizer to cancel diabetes drug. Available at: www.nytimes.com (Last accessed October 19, 2007).
109. Gonda I: The ascent of pulmonary drug delivery. J Pharm Sci. 2000;89:940-945.
110. Klinger-Strobel M, Lautenschläger C, Fischer D, Mainz JG, Bruns T, Tuchscherr L, Pletz MW, and Makarewicz O: Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - Where do we stand? Expert Opin Drug Deliv. 2015;12:1351-1374.
111. Barry PJ, and Jones AM: New and emerging treatments for cystic fibrosis. Drugs. 2015;75:1165-1175.
112. Carnovale V, Iacotucci P, Cellurale M, d'Ippolito M, Buonauriou S, Celardo A, and Ferrara N: Inhalation therapy in cystic fibrosis. ACTA Biomed. 2014;85(S4):7-9.
113. Cyranoski D: Threat of pandemic brings flu drug back to life. Nat Med. 2005;11:909.
114. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, and Connor EM: Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356: 685-696.
115. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, and Sepulveda-Amor J: Aerosolized measles and measles-rubella vaccine induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Org. 2002;80:806-812.
116. Agarkhedkar S, Kulkarni PS, Winston S, Sievers R, Dhere RM, Gunale B, Powell K, Rota PA, and Papania M: Safety and immunogenicity of dry powder measles vaccine adminstered by inhalation: A randomized controlled Phase I clinical trial. Vaccine. 2014;32:6791-6797.
117. Rubin BK: Air and soul: The science and application of aerosol therapy. Respir Care. 2010;55:911-921.
118. Davidson L: Vaping takes off as e-cigarette sales break through $6bn. The Telegraph 2015. Available at: www. telegraph.co.uk/finance/newsbysector/retailandconsumer/ 11692435/Vaping-takes-off-as-e-cigarette-sales-breakthrough-6bn.html (Last accessed June 23, 2015).
119. Food and Drug Administration: Deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco products. Available at: www.federalregister.gov/articles/2016/05/10/2016-10685/deeming-tobaccoproducts-to-be-subject-to-the-federal-food-drug-and-cosmeticact-as-amended-by-the (Last accessed May 10, 2016).
120. Centers for Medicare and Medicaid Services: National Health Expenditures Projections 2011-2021. Available at: www.cms.gov/Research-Statistics-data-and-Systems/ Statistics-Trends-and-Reports/NationalHealthExpendData/ Downloads/Proj2011PDF.pdf (Last accessed January 22, 2016).
121. Karst KR: Jumping legal hurdles with the U.S. FDA: The generic inhaler challenge. Respir Drug Deliv Asia. 2014;1: 151-158.
122. Hall JR, and DenyerMD: Contrasting regulatory equivalence demands between the EU and the US: History, law, markets and future needs. Respir Drug Deliv Eur. 2007;1:109-118.
123. Byron PR: Can we move toward harmonized requirements for bioequivalence of inhalers? Respir Drug Deliv Eur. 2007;1:151-158.
124. Fuglsang A, Leach CL, Mayers I, and Chowdhury BA: Therapeutic equivalence of inhaled corticosteroids - Workshop on regional differences in regulatory requirements. Respir Drug Deliv. 2008;1:133-150.
125. U.S. Food and Drug Administration: Draft guidance on albuterol sulfate. 2013. (http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ ucm346985.pdf) (accessed September 8, 2016).
126. U.S. Food and Drug Administration: Draft guidance on fluticasone propionate; salmeterol xinafoate. 2013. (http:// www.fda.gov/downloads/drugs/guidancecompliance regulatoryinformation/guidances/ucm367643.pdf) (accessed September 8, 2016).
127. Singh S, Kanbar-Agha F, and Sharafkhaneh A: Novel aerosol delivery devices. Semin Respir Crit Care Med. 2015;36:543-551.
128. Van sickle D, Maenner MJ, Barrett MA, and Marcus JE: Monitoring and improving compliance and asthma control: Mapping inhaler use for feedback to patients, physicians and payers. Respir Drug Deliv Eur. 2013;1:119-130.